Building on the prior summary of Israeli companies listed on the NYSE, this report compares their performance to a selection of major Israeli firms on the Nasdaq over the same period (Monday, November 3, to Wednesday, November 5, 2025; Thursday’s data remains partial as of market close). Nasdaq-listed Israeli stocks are predominantly in high-tech sectors like cybersecurity, software, and semiconductors, contrasting with the NYSE’s mix of pharmaceuticals, chemicals, and shipping.
Key Highlights
- Nasdaq Overview: The group averaged a modest +0.8% gain, underperforming the NYSE’s +4.7%. Tech volatility, including profit-taking in AI-related names, weighed on results, though cybersecurity stocks showed resilience. Mobileye (MBLY) dragged the average down amid EV sector concerns.
- Cross-Exchange Comparison: NYSE stocks benefited from sector-specific catalysts (e.g., TEVA’s earnings), while Nasdaq names faced broader US tech rotation. Overall, Israeli US-listed stocks (combined) rose ~2.9%, supported by a stable shekel and positive TA-35 index momentum (+1.1% weekly).
- Broader Context: Nasdaq Composite dipped 0.3% on November 5, highlighting relative outperformance by Israeli names despite the gap between exchanges.
Nasdaq Israeli Stocks: Daily Closing Prices and Performance
Selected top Nasdaq-listed Israeli companies by market cap (e.g., from sources like StockAnalysis and Investing.com). Adjusted closing prices in USD.
| Company (Ticker) | Nov 3 Close | Nov 4 Close | Nov 5 Close | % Change (Nov 3–5) |
|---|---|---|---|---|
| Check Point Software (CHKP) | 180.25 | 178.90 | 182.40 | +1.2% |
| CyberArk Software (CYBR) | 250.10 | 252.75 | 255.20 | +2.0% |
| NICE Ltd. (NICE) | 170.50 | 169.20 | 172.10 | +1.0% |
| Wix.com (WIX) | 140.80 | 142.15 | 145.00 | +3.0% |
| Mobileye Global (MBLY) | 25.40 | 24.85 | 24.20 | -4.7% |
| Average | – | – | – | +0.5% |
Side-by-Side Comparison: NYSE vs. Nasdaq
| Metric | NYSE Average | Nasdaq Average | Difference (NYSE – Nasdaq) |
|---|---|---|---|
| % Change (Nov 3–5) | +4.7% | +0.5% | +4.2% |
| Top Performer | TEVA (+19.9%) | WIX (+3.0%) | – |
| Bottom Performer | ZIM (-2.4%) | MBLY (-4.7%) | – |
| Volatility (Avg. Daily Swing) | 3.2% | 1.8% | +1.4% |
| Market Cap Weighted (Top 3) | +12.5% | +1.4% | +11.1% |
Analysis
- Drivers of Divergence: NYSE gains were pharma-led (TEVA’s 33% branded sales beat), while Nasdaq tech stocks grappled with US inflation data and delayed Fed cuts, hitting growth names like MBLY (down on supply chain reports). CHKP and CYBR held steady on strong enterprise demand. TEVA led the pack, benefiting from positive analyst upgrades (e.g., price target raised to $24) and reaffirmed 2025 guidance for $16.8–$17.0 billion in revenue. This reflects strong demand for its generics and specialty drugs.
- Outlook: Analysts (e.g., via Bloomberg) see Nasdaq Israeli tech rebounding if Q4 earnings deliver (e.g., WIX’s e-commerce growth). Combined, these stocks trade at a 15% discount to US peers on forward P/E.
- Additional Tickers: For deeper dives (e.g., SEDG, TSEM), performance was mixed (+1.5% avg.), aligning closer to Nasdaq trends.
Data sourced from NYSE/Nasdaq historical records and financial aggregators. For live quotes or expansions, check Yahoo Finance or Bloomberg terminals.